LabGenius has developed EVA - an autonomous AI-driven evolution engine for the discovery of high-value protein components. The company uses its platform technology to develop new products in partnership with world-leading multinationals. LabGenius is based in Central London and run by a passionate team of synthetic biologists, data scientists and engineers.
We engineer proteins with both enhanced and entirely novel functionality. The technology underpinning this capability integrates machine learning, gene synthesis and robotic automation.
In nature, organisms evolve slowly over many generations. This is a remarkably inefficient and unpredictable process because evolution never learns from its mistakes (or successes). We’ve made evolution more intelligent by unpicking the design rules which underpin biological systems. In simple terms, we can predict which mutations will improve a biological design. Our predictive power improves every day as we continuously extract design rules from both propriety and open-access data sets using our novel machine learning algorithms.
Using our proprietary gene synthesis technology, we can accurately manufacture trillions of unique DNA sequences (termed libraries). Unlike traditional synthesis methods, our technology does not involve either long-sequence hybridisation or polymerase chain reaction (PCR) steps. As a consequence, our libraries do not suffer from either diversity loss (through sub-pool amplification & polymerase-specific biasing) or low fidelity (due to miss-annealing between DNA strands). LabGenius has a patent pending on its novel multiplexed gene synthesis technology.
We're closing the loop on the protein engineering process through end-to-end automation. This enables us to continuously test new biological designs which EVA has predicted will perform well. Through continuous empirical testing, we are rapidly generating large & high quality proprietary datasets which feed our machine learning algorithms and ultimately make EVA smarter.
LabGenius develops products in partnership with leading multinationals. This model enables us to exploit our technology across several markets while remaining tightly focussed on our core competencies.
Proteins (e.g. enzymes and antibodies) are widely deployed across the pharmaceutical industry for both diagnostic and therapeutic purposes.
EVA, our AI-driven evolution engine, is currently learning how to optimally enhance the stability of therapeutic proteins in protease rich environments (e.g. the gastrointestinal (GI) tract, tumour microenvironments and inflamed tissues). This capability will ultimately enable the delivery of novel therapies for unmet clinical needs.
Within the advanced materials market, engineered proteins can be used to form high value coatings, adhesives, fibres, catalysts and sensors. LabGenius has completed several development projects within this space that have been backed by the UK Ministry of Defence (MoD). The company is additionally engaged in the collaborative development of advanced materials with leading aerospace and defence multinationals.
Engineered proteins (e.g. peptides & enzymes) are deployed extensively within the personal care industry. For example, within the context of skin and haircare products proteins can provide anti-wrinkle, firming, volumising and lightening effects. Using AI-driven high throughput empirical screening, it is possible to engineer novel proteins with enhanced functionality and activity.
Dr James Field, Founder & CEO
James completed his EPSRC-funded PhD at Imperial College London where he developed a platform for targeted drug delivery using re-engineered protein nanocages. Prior to his PhD, James completed a BSc in Biology with Microbiology (1st Class) and an MRes in Systems and Synthetic Biology (Distinction), at Imperial College London.
James is an active member of the synthetic biology community having participated in the iGEM competition both as an undergraduate (2009), advisor (2011) and judge (2016).
In 2017, James was awarded the BBSRC Innovator of the Year award for early career impact. In 2018, James was featured on Forbes' 30 Under 30 list for Science & Healthcare. James is also a fellow of the prestigious Synthetic Biology Leadership Excellence Accelerator Program (LEAP).
Outside of work, James enjoys time with his daughter, reading science fiction and drinking loose leaf Earl Grey tea.
Dr Adam Tomassi-Russell, Chief Commercial Officer & MD
Adam is responsible for Strategy, Business Development, Marketing, Commercial Partnerships and Product Management.
Adam studied Chemistry (MSci) at Imperial College London where he graduated top of his year; he subsequently completed his PhD at the University of Oxford. Before joining LabGenius, Adam spent several years working at Johnson Matthey (UK FTSE 100 company) where he was part of the JM Group Innovation and New Business Development team.
In his spare time, Adam enjoys cooking, reading and the outdoors.
Dr Pedro Tizei, Automation Scientist
Pedro is responsible for the development and optimisation of LabGenius' high throughput screening technologies.
During his PhD studies, in Structural and Molecular Biology at UCL, Pedro developed a strategy for the directed evolution of flexible loops in proteins. This novel technology was used to accelerate the exploration of functional sequence space in β-lactamases. Prior to his PhD, Pedro obtained an MSc in Genetics and Molecular Biology at UNICAMP and a BSc in Biological Sciences from USP, both in Brazil.
Outside work, Pedro spends his time reading about the world outside biology, trying out interesting food and drinks, and running slowly.
Dr Annelie Oswald, Platform Scientist
Annelie is responsible for product development at LabGenius.
Prior to her work at LabGenius, Annelie was an MRC Career Development Fellow at the Crick Institute. Her research focused on the reconstruction of a developmental clock using synthetic biology, in which she established a microfluidics platform for single cell long-term-time-lapse microscopy. Annelie previously completed her PhD in Biology at the MPI-CBG in Dresden, Germany. She received a MSc in Molecular Bioengineering from the BIOTEC/TU-Dresden in Germany and a BSc in Biochemical Engineering from Rutgers University in NJ, USA.
Annelie is a published scientist with extensive interdisciplinary experience from developmental and molecular biology to engineering and mathematical modelling.
Dr Ben Mackrow, Synthetic Biologist
Ben is responsible for the development and optimisation of LabGenius' library construction technology.
Ben completed his PhD in Synthetic Biology at Imperial College London in late 2016. His research focused on the development of an in-vivo directed evolution technology. Ben received his MRes in Synthetic Biology (Distinction) from University College London in 2012 and his BSc in Biomedical Science/Forensics from Brunel University in 2011.
Most of his time away from work is spent playing football (managing/captaining his Saturday team). Alternatively you'll find him watching live-comedy somewhere in London, or enjoying the snow in the Alps.
Mo Niknafs, COO
Mo is responsible for operations, brand, and non-dilutive financing.
Mo completed his MEng in Mechanical Engineering at Imperial College London. For his Masters project, he developed polydopamine-mediated antimicrobial coatings (1st Class).
Mo co-founded Imperial College Design Collective and was a founding committee member of Imperial Create Lab.
In his free time, Mo enjoys martial arts, music production, cycling and tidying.
Harry Rickerby, CSO
Harry is responsible for overseeing the development of LabGenius' entire technology stack.
Harry studied at Imperial College, attaining an MRes in Systems and Synthetic Biology (Distinction).
Harry was LabGenius’ first employee, co-inventing the company's foundational library synthesis technology and applying this to numerous directed evolution projects. Harry also serves as a technical advisor to the EPSRC-funded Portabolomics project at Newcastle University.
Harry loves kayaking, hiking in the mountains, noodling on his guitar and home-brewing.
Claire Perry, Administrative Assistant
Claire provides vital operational and administrative support to the team. Her responsibilities are diverse and span office management, HR and compliance.
Claire studied Immunology (BSc Hons) at the University of Glasgow (2013-2017) where she specialized in biotherapeutics for immunomodulation.
Oli Hall, Data Engineer
Oli is responsible for developing the scalable data platform that processes and stores the biological data generated by our platform.
Oli studied Computing (MEng) at Imperial College (2007-2012). For the past three years, he's worked as a Data Engineer at DueDil. Whilst there, he's tackled everything from onboarding new data, leading a team, and improving best practices and cost efficiency across the engineering team. Most recently, he has been engaged in rebuilding the entire Data Platform for DueDil from the ground up, with a focus on speed, efficiency and usability.